Results 91 to 100 of about 7,263 (276)

“ONDANSETRON VERSUS PALONOSETRON PARA EL MANEJO DE NÁUSEA Y VÓMITO POSTOPERATORIO EN COLECISTECTOMÍA LAPAROSCÓPICA EN ISSEMYM SATÉLITE” [PDF]

, 2013
Antecedentes: Las náuseas y vómitos postoperatorios (NVPO) son de los mayores problemas en anestesia, con una alta incidencia en cirugía laparoscópica.
Márquez Zapien, Cuitláhuac, Ramírez Romero, Salvador Iván   +1 more
core  

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2 [PDF]

, 2017
Objective: An integrated analysis was undertaken to characterize the antitumor activity and safety profile of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with relapsed high-grade ovarian carcinoma (HGOC). Methods: Eligible
Bell-McGuinn, Katherine, Brenton, James D., Castro, Cesar M., Chen, Lee-may, Coleman, Robert L., Giordano, Heidi, Goble, Sandra, Konecny, Gottfried E., Kristeleit, Rebecca S., Leary, Alexandra, Lin, Kevin K., Ma, Ling, Maloney, Lara, Mcneish, Iain A., Oaknin, Ana, Oza, Amit M., O’Malley, David M., Provencher, Diane, Raponi, Mitch, Ray-Coquard, Isabelle, Rolfe, Lindsey, Shapira-Frommer, Ronnie, Sun, James, Swisher, Elizabeth M., Tinker, Anna V.   +24 more
core   +1 more source

The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study

Cureus, 2022
Background Female gender, young age, first chemotherapy cycle, and low alcohol intake have all been linked to an increased risk of nausea and vomiting from chemotherapy.
B. Vaswani, P. Dattatreya, H. Barkate, S. Bhagat, Saiprasad Patil, Amit Y Jadhav   +5 more
semanticscholar   +1 more source

Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron

Therapeutics and Clinical Risk Management, 2015
Michelle Zhou, Marko Popovic, Mark Pasetka, Natalie Pulenzas, Soha Ahrari, Edward Chow, Carlo DeAngelis Department of Pharmacy, Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada Purpose: Nausea and
Zhou M, Popovic M, Pasetka M, Pulenzas N, Ahrari S, Chow E, DeAngelis C   +6 more
doaj  

A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide

Cancer Medicine, 2020
Purpose To investigate whether palonosetron is better than granisetron in preventing chemotherapy‐induced nausea and vomiting (CINV) in a three‐drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on ...
Koji Matsumoto, Masato Takahashi, Kazuhiko Sato, Akihiko Osaki, Toshimi Takano, Yoichi Naito, Kazuo Matsuura, Kenjiro Aogi, Kimiko Fujiwara, Kenji Tamura, Motoi Baba, Shinya Tokunaga, Gen Hirano, Shigeru Imoto, Chieko Miyazaki, Kazuhiro Yanagihara, Chiyo K. Imamura, Yasutaka Chiba, Toshiaki Saeki   +18 more
doaj   +1 more source

5-HT3 Receptor Brain-Type B-Subunits are Differentially Expressed in Heterologous Systems. [PDF]

, 2015
Genes for five different 5-HT3 receptor subunits have been identified. Most of the subunits have multiple isoforms, but two isoforms of the B subunits, brain-type 1 (Br1) and brain-type 2 (Br2) are of particular interest as they appear to be abundantly ...
Bouzat, Cecilia, Corradi, Jeremias, Lummis, Sarah CR, McGonigle, Ian, Price, Kerry L, Thompson, Andrew J   +5 more
core   +3 more sources

CYP2D6 genotype and associated 5‐HT3 receptor antagonist outcomes: A systematic review and meta‐analysis

Clinical and Translational Science, Volume 18, Issue 2, February 2025.
Abstract 5‐hydroxytryptamine‐3 (5‐HT3) receptor antagonists including ondansetron, tropisetron, dolasetron, palonosetron, granisetron, and ramosetron are commonly used to prevent and treat nausea and vomiting. Most of these medications are at least partially metabolized via the highly polymorphic CYP2D6 enzyme, resulting in variations of metabolism ...
Claire Moore, Elizabeth Williams, Roxanne Dyas, Andreas Halman, Tayla Stenta, Dhrita Khatri, David A. Elliott, Peter W Lange, Kelly E. Caudle, Rachel Conyers   +9 more
wiley   +1 more source

Comparison of ondansetron, tropisetron, and palonosetron for the prevention of postoperative nausea and vomiting after middle ear surgery

Current Therapeutic Research, 2019
: Background: Postoperative nausea and vomiting (PONV) are 2 of the most frequent adverse effects of anesthesia. PONV prolongs hospital stays and also delays the recovery of patients.
Ahmet Aydin, MD, Mustafa Kaçmaz, MD, Adem Boyaci, MD   +2 more
doaj   +1 more source

An Integrated In Silico and In Vivo Approach to Identify Protective Effects of Palonosetron in Cisplatin-Induced Nephrotoxicity

Pharmaceuticals, 2020
Cisplatin is widely used to treat various types of cancers, but it is often limited by nephrotoxicity. Here, we employed an integrated in silico and in vivo approach to identify potential treatments for cisplatin-induced nephrotoxicity (CIN).
Eri Wakai, Yuya Suzumura, Kenji Ikemura, Toshiro Mizuno, Masatoshi Watanabe, Kazuhiko Takeuchi, Yuhei Nishimura   +6 more
doaj   +1 more source

Seizure associated with palonosetron

Supportive Care in Cancer, 2009
In 2003, FDA approved palonosetron as an effective drug for the control ofnausea and vomitingassociated tochemotherapy. Palonosetron is suggested in case of emetogenic chemotherapy schedules, in particular, in the case of cisplatin, high-dose cyclophosphamide, and anthracyclines.
Zambelli A, Sagrada P, Pavesi L
openaire   +3 more sources